Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

38.49 +0.18 (+0.48%)
Streaming Delayed Price Updated: 12:48 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Looking Into Royalty Pharma's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Expert Ratings for Royalty Pharma ↗
  Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Royalty Pharma: Q2 Earnings Insights ↗
  Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Expert Ratings for Royalty Pharma ↗
Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
From Royalty Pharma plc
Via GlobeNewswire
News headline image
6 Stocks Warren Buffett Completely Exited in 2022 ↗
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio. 
Via The Motley Fool
News headline image
Royalty Pharma Announces Expansion of Senior Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Royalty Pharma Reports Third Quarter 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022
From Royalty Pharma plc
Via GlobeNewswire
News headline image
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position ↗
There may be more trouble on the horizon for these stocks than most investors are seeing right now. 
Via The Motley Fool
News headline image
Royalty Pharma Declares Fourth Quarter 2022 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added. 
Via Benzinga
News headline image
Royalty Pharma Announces Expansion of Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces R&D Funding Collaboration With Merck
Novel collaboration structure supports pipeline innovation 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗
 
Via Benzinga
News headline image
Royalty Pharma's Return On Capital Employed Insights ↗
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters. 
Via Benzinga
News headline image
Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals ↗
Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing. 
Via Benzinga
News headline image
Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royalty Pharma PLC (NASDAQ: RPRX) is going higher. "Hold on to it." 
Via Benzinga
News headline image
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests ↗
 
Via Benzinga
News headline image
Warren Buffett Stocks: Royalty Pharma plc ↗
As of March 31st, 2022, Buffett’s Berkshire Hathaway owned about 1.5 million shares of Royalty Pharma plc for a market value of $58.3 million. Let's analyze the healthcare company in greater detail. 
Via Talk Markets
News headline image
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation' ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Management of Technology Companies Continue Selling - Zillow (Z) ↗
In a week where we saw most market indices rebound sharply, insiders scaled back their buying after three weeks of elevated buying. Buying declined by 64% in absolute dollar terms and 26% in terms of... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.